A SARS-CoV-2 RBD vaccine fused to the chemokine MIP-3α elicits sustained murine antibody responses over 12 months and enhanced lung T-cell responses.
Gordy JT, Hui Y, Schill C, Wang T, Chen F, Fessler K, Meza J, Li Y, Taylor AD, Bates RE, Karakousis PC, Pekosz A, Sachithanandham J, Li M, Karanika S, Markham RB.
Gordy JT, et al.
Front Immunol. 2024 Feb 2;15:1292059. doi: 10.3389/fimmu.2024.1292059. eCollection 2024.
Front Immunol. 2024.
PMID: 38370404
Free PMC article.